200 related articles for article (PubMed ID: 35589643)
1. [Steroids-Resistant EGPA-Induced Neuropathy with Acute Disease Progression: How to Use Mepolizumab as Novel Targeted Agent].
Hattori N
Brain Nerve; 2022 May; 74(5):531-536. PubMed ID: 35589643
[TBL] [Abstract][Full Text] [Related]
2. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
3. Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies-negative eosinophilic granulomatosis with polyangiitis.
Bouiller K; Samson M; Eicher JC; Audia S; Berthier S; Leguy V; Humbert O; Martin L; Lorgis L; Cottin Y; Bonnotte B; Lorcerie B
Intern Med J; 2014 Sep; 44(9):928-31. PubMed ID: 25201426
[TBL] [Abstract][Full Text] [Related]
4. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
[TBL] [Abstract][Full Text] [Related]
5. Anti-neutrophil Cytoplasmic Antibody-negative Eosinophilic Granulomatosis with Polyangiitis Complicated with Peripheral Neuropathy that Underwent Remission Induction with Mepolizumab Monotherapy.
Nishihara M; Suzuki M; Asatani S; Nagasawa Y; Tsukamoto M; Akiya K; Kobayashi H; Kitamura N; Nakamura H
Intern Med; 2023 Oct; 62(19):2895-2900. PubMed ID: 36725044
[TBL] [Abstract][Full Text] [Related]
6. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
7. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
Ozola L; Aleksejeva E; Stoldere D; Dāvidsone Z; Šantere R; Grantiņa I; Cīrule I; Krams A
Pediatr Pulmonol; 2023 Mar; 58(3):973-979. PubMed ID: 36404638
[TBL] [Abstract][Full Text] [Related]
9. Hypertrophic pachymeningitis in eosinophilic granulomatosis with polyangiitis.
Izuka S; Yamashita H; Takahashi Y; Kaneko H
Mod Rheumatol Case Rep; 2022 Jan; 6(1):80-82. PubMed ID: 34480185
[TBL] [Abstract][Full Text] [Related]
10. [Current treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)].
Moosig F; Holle J
Z Rheumatol; 2019 May; 78(4):333-338. PubMed ID: 30627842
[TBL] [Abstract][Full Text] [Related]
11. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
12. ANCA-negative ANCA-associated vasculitis: pitfalls of the 'vasculitis screen'.
Cooke H; Wells M; Miller K; Medford ARL; Patel S
Clin Med (Lond); 2023 Nov; 23(6):630-632. PubMed ID: 38065599
[TBL] [Abstract][Full Text] [Related]
13. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.
Bloom JL; Langford CA; Wechsler ME
Rheum Dis Clin North Am; 2023 Aug; 49(3):563-584. PubMed ID: 37331733
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I; Angelopoulos A; Daoussis D
Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
[TBL] [Abstract][Full Text] [Related]
16. [Steroids-Resistant EGPA-Induced Neuropathy with Acute Disease Progression: How to Select Remission-Induction/Maintenance Therapy Based on The Characteristics].
Takeshita Y
Brain Nerve; 2022 May; 74(5):525-530. PubMed ID: 35589642
[TBL] [Abstract][Full Text] [Related]
17. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of ANCA-associated vascularitides].
Guillevin L; Pagnoux C
Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
